Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Welcome to the Precipio Q4 and Year-End 2024 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator ...

Precipio Inc (PRPO) reports positive cash flow and revenue growth, while addressing challenges in its product division and enhancing market visibility for 2025. Precipio ( NASDAQ:PRPO ) Full Year ...

NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March ...

Precipio Inc (NASDAQ:PRPO) achieved its goal of reaching break-even by the end of 2024, with positive adjusted EBITDA and positive cash flow. The company reported a revenue growth of nearly 26% in ...

Precipio, Inc. (NASDAQ:PRPO), a company specializing in laboratory analytical instruments with a market capitalization of $8.6 million and annual revenue of $18.5 million, announced a change in ...

Precipio (NASDAQ:PRPO) just reported results for the first quarter of 2024. Precipio reported earnings per share of -$1.46. This was below the analyst estimate for EPS of -70 cents. The company ...

Explore Precipio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PRPO. U.S. stocks traded higher toward the end of trading, with Dow Jones gaining more ...

Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense ...

Welcome to the Precipio Q4 and Year-End 2024 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being ...

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell ...

Precipio, Inc. (NASDAQ:PRPO), a company specializing in laboratory analytical instruments with a market capitalization of $8.6 million and annual revenue of $18.5 million, announced a change in its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...